Regen Biopharma issues 20,068 Series A Preferred shares for consulting; amends sublease

Regen BioPharma Inc

Issued 20,068 Series A Preferred shares to Value Quest Inc. for one-year social media consulting services.
Consulting covers Facebook and Twitter management; shares are unregistered restricted securities.
Amended sublease with BST Partners (controlled by CEO David Koos) to reimburse shared expenses in addition to $5k/month base rent.
Subtenant also required to pay shared expenses retroactive to January 1, 2024, per amendment.
Both transactions involve related party: David Koos is CEO and also controls BST Partners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.